eISSN: 2299-0046
ISSN: 1642-395X
Advances in Dermatology and Allergology/Postępy Dermatologii i Alergologii
Current issue Archive Manuscripts accepted About the journal Abstracting and indexing Subscription Contact Instructions for authors
SCImago Journal & Country Rank
vol. 33
Original paper

Serum vitamin D level – the effect on the clinical course of psoriasis

Beata Bergler-Czop, Ligia Brzezińska-Wcisło

Adv Dermatol Allergol 2016; XXXIII (6): 445-449
Online publish date: 2016/12/02
View full text
Get citation
JabRef, Mendeley
Papers, Reference Manager, RefWorks, Zotero
Introduction: Psoriasis is a hyperproliferative disorder of the skin, and vitamin D analogs are widely used in its treatment. It is evident that ultraviolet radiation enables vitamin D3 (cholecalciferol) formation in the epidermis, and this product is further converted into the active metabolites 25-hydroxycholecalciferol and 1,25-hydroxycholecalciferol, which exert several important effects on the skin. The disruption in proper functioning of the skin which occurs in psoriasis leads to a loss of capacity for cutaneous synthesis of vitamin D3. In consequence, it activates a vicious circle that impairs homeostasis of the skin and results in a progressive decrease in the level of vitamin D in the whole human body.

Aim: To estimate the prevalence of vitamin D serum deficiency in patients with psoriasis and analyse the association of vitamin D food intake with clinical features.

Material and methods: Forty adults with psoriasis and 40 healthy subjects (control group) were recruited. Psoriasis plaques were diagnosed and evaluated by the PASI scale. Collected blood samples enabled measurement of serum vitamin D level by assessment with the immunoenzyme technique.

Results: The analysis with the Mann-Whitney U test revealed a statistically significant difference in 25-hydroxycholecalciferol level between healthy individuals and patients with psoriasis (p = 0.048). In both groups (control and psoriatic) the level of 25-hydroxycholecalciferol was seriously deficient (< 50 nmol/l). There was also a negative correlation of 25-hydroxycholecalciferol serum level with both PASI (r = –0.43) and the duration of psoriasis (r = –0.53).

Conclusions: It is necessary to bear in mind that not only the ingestion of food rich in vitamin D is necessary, but also the production of vitamin D with sun exposure. The quantity of 25-hydroxycholecalciferol is very important both in the general population and in patients with psoriasis, because these groups have a distinct metabolism.

psoriasis, 25-hydroxycholecalciferol, serum level

Suárez-Varela MM, Reguera-Leal P, Grant WB, et al. Vitamin D and psoriasis pathology in the Mediterranean region, Valencia (Spain). Int J Environ Res Public Health 2014; 11: 12108-17.
Leyssens C, Verlinden L, Verstuyf A. The future of vitamin D analogs. Front Physiol 2014; 5: 122.
Millsop JW, Bhatia BK, Debbaneh M, et al. Diet and psoriasis, part III: role of nutritional supplements. J Am Acad Dermatol 2014; 71: 561-9.
Finamor DC, Sinigaglia-Coimbra R, Neves LC, et al. A pilot study assessing the effect of prolonged administration of high daily doses of vitamin D on the clinical course of vitiligo and psoriasis. Dermatoendocrinol 2013; 5: 222-34.
Slominski A, Kim TK, Zmijewski MA, et al. Novel vitamin D photoproducts and their precursors in the skin. Dermatoendocrinol 2013; 5: 7-19.
Datta Mitra A, Raychaudhuri SP, Abria CJ, et al. 1alpha,25-dihydroxyvitamin-D3-3-bromoacetate regulates AKT/mTOR signaling cascades: a therapeutic agent for psoriasis. J Invest Dermatol 2013; 133: 1556-64.
Chiang KC, Yeh CN, Hsu JT, et al. Evaluation of the potential therapeutic role of a new generation of vitamin D analog, MART-10, in human pancreatic cancer cells in vitro and in vivo. Cell Cycle 2013; 12: 1316-25.
Morimoto S, Kumahara Y. A patient with psoriasis cured by 1 alpha-hydroxyvitamin D3. Med J Osaka Univ 1985; 35: 51-4.
Macejova D, Ondkova S, Jakubikova L, et al. MNU-induced mammary gland carcinogenesis: chemopreventive and therapeutic effects of vitamin D and Seocalcitol on selected regulatory vitamin D receptor pathways. Toxicol Lett 2011; 207: 60-72.
Wu-wong JR, Tian J, Golzman D. Vitamin D analogs as therapeutic agents: a clinical study update. Curr Opin Investing Drugs 2004; 5: 320-6.
Ala-Houhala MJ, Karppinen T, Vähävihu K, et al. Narrow-band ultraviolet B treatment boosts serum 25-hydroxyvitamin D in patients with psoriasis on oral vitamin D supplementation. Acta Derm Venereol 2014; 94: 146-51.
Okita H, Ohtsuka T, Yamakage A, Yamazaki S. Polymorphism of the vitamin D(3) receptor in patients with psoriasis. Arch Dermatol Res 2002; 294: 156-62.
Ahn CS, Awadalla F, Huang KE, et al. Patterns of vitamin D analog use for the treatment of psoriasis. J Drugs Dermatol 2013; 12: 906-10.
Griffin MD, Xing N, Kumar R. Gene expression profiles in dendritic cells conditioned by 1alpha,25-dihydroxyvitamin D3 analog. J Steroid Biochem Mol Biol 2004; 89-90: 443-8.
Ricceri F, Pescitelli L, Tripo L, Prignano F. Deficiency of serum concentration of 25-hydroxyvitamin D correlates with severity of disease in chronic plaque psoriasis. J Am Acad Dermatol 2013; 68: 511-2.
Orgaz-Molina J, Buendía-Eisman A, Arrabal-Polo MA, et al. Deficiency of serum concentration of 25-hydroxyvitamin D in psoriatic patients: a case-control study. J Am Acad Dermatol 2012; 67: 931-8.
Kudish AI, Harari M, Evseev EG. The measurement and analysis of normal incidence solar UVB radiation and its application to the photoclimatherapy protocol for psoriasis at the Dead Sea, Israel. Photochem Photobiol 2011; 87: 217-22.
Menter A, Gold LS, Bukhalo M, et al. Calcipotriene plus betamethasone dipropionate topical suspension for the treatment of mild to moderate psoriasis vulgaris on the body: a randomized, double-blind, vehicle-controlled trial. J Drugs Dermatol 2013; 12: 92-8.
Feldmeyer L, Shojaati G, Spanaus KS, et al. Phototherapy with UVB narrowband, UVA/UVBnb, and UVA1 differentially impacts serum 25-hydroxyvitamin-D3. J Am Acad Dermatol 2013; 69: 530-6.
Katz U, Shoenfeld Y, Zakin V, et al. Scientific evidence of the therapeutic effects of dead sea treatments: a systematic review. Semin Arthritis Rheum 2012; 42: 186-200.
Li YC. Vitamin D regulation of the renin-angiotensin system. J Cell Biochem 2003; 88: 327-31.
Khandpur S, Bhari N. Newer targeted therapies in psoriasis. Indian J Dermatol Venereol Leprol 2013; 79: 47-52.
Akasaka E, Mabuchi T, Manabe Y, et al. Long-term efficacy of psoriasis vulgaris treatments: analysis of treatment with topical corticosteroid and/or vitamin D3 analog, oral cyclosporin, etretinate and phototherapy over a 35-year period, 1975-2010. J Dermatol 2013; 40: 238-43.
Quick links
© 2018 Termedia Sp. z o.o. All rights reserved.
Developed by Bentus.
PayU - płatności internetowe